This article is more than 5 years old. Information may no longer be current.

PDT may not limit angioid streak growth

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Current re-treatment criteria with photodynamic therapy “does not appear to limit the growth of choroidal neovascularization angioid streaks,” according to a study.

Bernhard Jurklies and colleagues at the University Hospital Essen in Germany prospectively enrolled 12 patients with choroidal neovascularization angioid streaks who underwent photodynamic therapy (PDT) with verteporfin. PDT use was based on the criteria for the treatment of age-related macular degeneration. Patients were followed between 24 and 60 months, researchers said.

The mean number of re-treatments was 3.3, with a range of two to seven, the authors said. Visual acuity improved by at least 1 line in 58%, and by at least 3 lines in 25% of the patients. One-quarter of the treated eyes and 75% of the contralateral eyes had a final VA of 20/200 or worse. At the last follow-up, a significant enlargement of the lesion size was noted.

The study is published in the April issue of Ophthalmic Research.